1
|
Barresi E, Baglini E, Poggetti V, Castagnoli J, Giorgini D, Salerno S, Taliani S, Da Settimo F. Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents. Molecules 2024; 29:2127. [PMID: 38731618 PMCID: PMC11085553 DOI: 10.3390/molecules29092127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Revised: 04/24/2024] [Accepted: 04/26/2024] [Indexed: 05/13/2024] Open
Abstract
Neurodegeneration is a gradual decay process leading to the depletion of neurons in both the central and peripheral nervous systems, ultimately resulting in cognitive dysfunctions and the deterioration of brain functions, alongside a decline in motor skills and behavioral capabilities. Neurodegenerative disorders (NDs) impose a substantial socio-economic strain on society, aggravated by the advancing age of the world population and the absence of effective remedies, predicting a negative future. In this context, the urgency of discovering viable therapies is critical and, despite significant efforts by medicinal chemists in developing potential drug candidates and exploring various small molecules as therapeutics, regrettably, a truly effective treatment is yet to be found. Nitrogen heterocyclic compounds, and particularly those containing the indole nucleus, which has emerged as privileged scaffold, have attracted particular attention for a variety of pharmacological applications. This review analyzes the rational design strategy adopted by different research groups for the development of anti-neurodegenerative indole-based compounds which have the potential to modulate various molecular targets involved in NDs, with reference to the most recent advances between 2018 and 2023.
Collapse
Affiliation(s)
- Elisabetta Barresi
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (E.B.); (V.P.); (J.C.); (F.D.S.)
| | - Emma Baglini
- Institute of Clinical Physiology, National Research Council of Italy, CNR Research Area, 56124 Pisa, Italy;
| | - Valeria Poggetti
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (E.B.); (V.P.); (J.C.); (F.D.S.)
| | - Jacopo Castagnoli
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (E.B.); (V.P.); (J.C.); (F.D.S.)
| | - Doralice Giorgini
- Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, Fisciano, 84084 Salerno, Italy;
| | - Silvia Salerno
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (E.B.); (V.P.); (J.C.); (F.D.S.)
| | - Sabrina Taliani
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (E.B.); (V.P.); (J.C.); (F.D.S.)
| | - Federico Da Settimo
- Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; (E.B.); (V.P.); (J.C.); (F.D.S.)
| |
Collapse
|
2
|
Jing L, Wei W, Meng B, Chantegreil F, Nachon F, Martínez A, Wu G, Zhao H, Song Y, Kang D, Brazzolotto X, Zhan P, Liu X. Rapid discovery and crystallography study of highly potent and selective butylcholinesterase inhibitors based on oxime-containing libraries and conformational restriction strategies. Bioorg Chem 2023; 134:106465. [PMID: 36933339 DOI: 10.1016/j.bioorg.2023.106465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2022] [Revised: 02/27/2023] [Accepted: 03/07/2023] [Indexed: 03/16/2023]
Abstract
Butyrylcholinesterase is regarded as a promising drug target in advanced Alzheimer's disease. In order to identify highly selective and potent BuChE inhibitors, a 53-membered compound library was constructed via the oxime-based tethering approach based on microscale synthesis. Although A2Q17 and A3Q12 exhibited higher BuChE selectivity versus acetylcholinesterase, the inhibitory activities were unsatisfactory and A3Q12 did not inhibit Aβ1-42 peptide self-induced aggregation. With A2Q17 and A3Q12 as leads, a novel series of tacrine derivatives with nitrogen-containing heterocycles were designed based on conformation restriction strategy. The results demonstrated that 39 (IC50 = 3.49 nM) and 43 (IC50 = 7.44 nM) yielded much improved hBuChE inhibitory activity compared to the lead A3Q12 (IC50 = 63 nM). Besides, the selectivity indexes (SI = AChE IC50 / BChE IC50) of 39 (SI = 33) and 43 (SI = 20) were also higher than A3Q12 (SI = 14). The results of the kinetic study showed that 39 and 43 exhibited a mixed-type inhibition against eqBuChE with respective Ki values of 1.715 nM and 0.781 nM. And 39 and 43 could inhibit Aβ1-42 peptide self-induced aggregation into fibril. X-ray crystallography structures of 39 or 43 complexes with BuChE revealed the molecular basis for their high potency. Thus, 39 and 43 are deserve for further study to develop potential drug candidates for the treatment of Alzheimer's disease.
Collapse
Affiliation(s)
- Lanlan Jing
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, PR China
| | - Wenxiu Wei
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, PR China
| | - Bairu Meng
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, PR China
| | - Fabien Chantegreil
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 1 Place du Général Valérie André, 91220, Brétigny-sur-Orge, France
| | - Florian Nachon
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 1 Place du Général Valérie André, 91220, Brétigny-sur-Orge, France
| | - Ana Martínez
- Centro de Investigaciones Biológicas Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain
| | - Gaochan Wu
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, PR China
| | - Huajun Zhao
- Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong 250012, PR China
| | - Yuning Song
- Department of Clinical Pharmacy, Qilu Hospital of Shandong University, Ji'nan, Shandong, PR China.
| | - Dongwei Kang
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, PR China.
| | - Xavier Brazzolotto
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 1 Place du Général Valérie André, 91220, Brétigny-sur-Orge, France.
| | - Peng Zhan
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, PR China.
| | - Xinyong Liu
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, PR China.
| |
Collapse
|
3
|
Liu C, Sang Z, Pan H, Wu Q, Qiu Y, Shi J. A Novel Multifunctional 5,6-Dimethoxy-Indanone-Chalcone-Carbamate Hybrids Alleviates Cognitive Decline in Alzheimer’s Disease by Dual Inhibition of Acetylcholinesterase and Inflammation. Front Aging Neurosci 2022; 14:922650. [PMID: 35860673 PMCID: PMC9289467 DOI: 10.3389/fnagi.2022.922650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Accepted: 06/08/2022] [Indexed: 11/24/2022] Open
Abstract
Backgrounds Alzheimer’s disease (AD) is a multifactorial neurodegenerative disease. The treatment of AD through multiple pathological targets may generate therapeutic efficacy better. The multifunctional molecules that simultaneously hit several pathological targets have been of great interest in the intervention of AD. Methods Here, we combined the chalcone scaffold with carbamate moiety and 5,6-dimethoxy-indanone moiety to generate a novel multi-target-directed ligand (MTDL) molecule (E)-3-((5,6-dimethoxy-1-oxo-1,3-dihydro-2H-inden-2-ylidene)-methyl)phenylethyl(methyl) carbamate (named AP5). In silico approaches were used to virtually predict the binding interaction of AP5 with AChE, the drug-likeness, and BBB penetrance, and later validated by evaluation of pharmacokinetics (PK) in vivo by LC-MS/MS. Moreover, studies were conducted to examine the potential of AP5 for inhibiting AChE and AChE-induced amyloid-β (Aβ) aggregation, attenuating neuroinflammation, and providing neuroprotection in the APP/PS1 model of AD. Results We found that AP5 can simultaneously bind to the peripheral and catalytic sites of AChE by molecular docking. AP5 exhibited desirable pharmacokinetic (PK) characteristics including oral bioavailability (67.2%), >10% brain penetrance, and favorable drug-likeness. AP5 inhibited AChE activity and AChE-induced Aβ aggregation in vivo and in vitro. Further, AP5 lowered Aβ plaque deposition and insoluble Aβ levels in APP/PS1 mice. Moreover, AP5 exerted anti-inflammatory responses by switching microglia to a disease-associated microglia (DAM) phenotype and preventing A1 astrocytes formation. The phagocytic activity of microglial cells to Aβ was recovered upon AP5 treatment. Importantly, chronic AP5 treatment significantly prevented neuronal and synaptic damage and memory deficits in AD mice. Conclusion Together, our work demonstrated that AP5 inhibited the AChE activity, decreased Aβ plaque deposition by interfering Aβ aggregation and promoting microglial Aβ phagocytosis, and suppressed inflammation, thereby rescuing neuronal and synaptic damage and relieving cognitive decline. Thus, AP5 can be a new promising candidate for the treatment of AD.
Collapse
Affiliation(s)
- Chan Liu
- Department of Pharmacology and Chemical Biology, Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Key Laboratory of Basic Pharmacology of Ministry of Education, Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China
| | - Zhipei Sang
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Hainan University, Haikou, China
| | - Hong Pan
- Department of Pharmacology and Chemical Biology, Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Key Laboratory of Basic Pharmacology of Ministry of Education, Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China
| | - Qin Wu
- Key Laboratory of Basic Pharmacology of Ministry of Education, Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China
| | - Yu Qiu
- Department of Pharmacology and Chemical Biology, Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- *Correspondence: Yu Qiu,
| | - Jingshan Shi
- Key Laboratory of Basic Pharmacology of Ministry of Education, Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China
- Jingshan Shi,
| |
Collapse
|
4
|
Semenov VE, Zueva IV, Mukhamedyarov MA, Lushchekina SV, Petukhova EO, Gubaidullina LM, Krylova ES, Saifina LF, Lenina OA, Petrov KA. Novel Acetylcholinesterase Inhibitors Based on Uracil Moiety for Possible Treatment of Alzheimer Disease. Molecules 2020; 25:molecules25184191. [PMID: 32932702 PMCID: PMC7571187 DOI: 10.3390/molecules25184191] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 09/07/2020] [Accepted: 09/10/2020] [Indexed: 12/14/2022] Open
Abstract
In this study, novel derivatives based on 6-methyluracil and condensed uracil were synthesized, namely, 2,4-quinazoline-2,4-dione with ω-(ortho-nitrilebenzylethylamino) alkyl chains at the N atoms of the pyrimidine ring. In this series of synthesized compounds, the polymethylene chains were varied from having tetra- to hexamethylene chains, and secondary NH, tertiary ethylamino, and quaternary ammonium groups were introduced into the chains. The molecular modeling of the compounds indicated that they could function as dual binding site acetylcholinesterase inhibitors, binding to both the peripheral anionic site and active site. The data from in vitro experiments show that the most active compounds exhibit affinity toward acetylcholinesterase within a nanomolar range, with selectivity for acetylcholinesterase over butyrylcholinesterase reaching four orders of magnitude. In vivo biological assays demonstrated the potency of these compounds in the treatment of memory impairment using an animal model of Alzheimer disease.
Collapse
Affiliation(s)
- Vyacheslav E. Semenov
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Arbuzov str. 8, 420088 Kazan, Russia; (I.V.Z.); (L.M.G.); (E.S.K.); (L.F.S.); (O.A.L.)
- Correspondence: (V.E.S.); (K.A.P.); Tel.: +7-843-279-47-09 (V.E.S.); +7-843-273-93-64 (K.A.P.)
| | - Irina V. Zueva
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Arbuzov str. 8, 420088 Kazan, Russia; (I.V.Z.); (L.M.G.); (E.S.K.); (L.F.S.); (O.A.L.)
| | - Marat A. Mukhamedyarov
- Institute of Neuroscience, Kazan State Medical University, 420012 Kazan, Russia; (M.A.M.); (E.O.P.)
| | - Sofya V. Lushchekina
- Emanuel Institute of Biochemical Physics, Kosygina st. 4, 119334 Moscow, Russia;
| | - Elena O. Petukhova
- Institute of Neuroscience, Kazan State Medical University, 420012 Kazan, Russia; (M.A.M.); (E.O.P.)
| | - Lilya M. Gubaidullina
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Arbuzov str. 8, 420088 Kazan, Russia; (I.V.Z.); (L.M.G.); (E.S.K.); (L.F.S.); (O.A.L.)
| | - Evgeniya S. Krylova
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Arbuzov str. 8, 420088 Kazan, Russia; (I.V.Z.); (L.M.G.); (E.S.K.); (L.F.S.); (O.A.L.)
| | - Lilya F. Saifina
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Arbuzov str. 8, 420088 Kazan, Russia; (I.V.Z.); (L.M.G.); (E.S.K.); (L.F.S.); (O.A.L.)
| | - Oksana A. Lenina
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Arbuzov str. 8, 420088 Kazan, Russia; (I.V.Z.); (L.M.G.); (E.S.K.); (L.F.S.); (O.A.L.)
| | - Konstantin A. Petrov
- Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Arbuzov str. 8, 420088 Kazan, Russia; (I.V.Z.); (L.M.G.); (E.S.K.); (L.F.S.); (O.A.L.)
- Institute of Fundamental Medicine and Biology, Kazan Federal University, Kremlyovskaya str., 18, 420008 Kazan, Russia
- Correspondence: (V.E.S.); (K.A.P.); Tel.: +7-843-279-47-09 (V.E.S.); +7-843-273-93-64 (K.A.P.)
| |
Collapse
|
5
|
Lalut J, Payan H, Davis A, Lecoutey C, Legay R, Sopkova-de Oliveira Santos J, Claeysen S, Dallemagne P, Rochais C. Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT 4 receptors activities for the treatment of Alzheimer's disease. Sci Rep 2020; 10:3014. [PMID: 32080261 PMCID: PMC7033111 DOI: 10.1038/s41598-020-59805-7] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2019] [Accepted: 01/30/2020] [Indexed: 01/09/2023] Open
Abstract
A rigidification strategy was applied to the preclinical candidate donecopride, an acetylcholinesterase inhibitor possessing 5-HT4R agonist activity. Inspired by promising bioactive benzisoxazole compounds, we have conducted a pharmacomodulation study to generate a novel series of multitarget directed ligands. The chemical synthesis of the ligand was optimized and compounds were evaluated in vitro against each target and in cellulo. Structure-activity relationship was supported by docking analysis in human acetylcholinesterase binding site. Among the synthesized compounds, we have identified a novel hybrid 32a (3-[2-[1-(cyclohexylmethyl)-4-piperidyl]ethyl]-4-methoxy-1,2-benzoxazole) able to display nanomolar acetylcholinesterase inhibitory effects and nanomolar Ki for 5-HT4R.
Collapse
Affiliation(s)
- Julien Lalut
- Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France
| | - Hugo Payan
- IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France
| | - Audrey Davis
- Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France
| | - Cédric Lecoutey
- Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France
| | - Rémi Legay
- Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France
| | | | | | - Patrick Dallemagne
- Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France
| | - Christophe Rochais
- Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France.
| |
Collapse
|
6
|
Zueva I, Dias J, Lushchekina S, Semenov V, Mukhamedyarov M, Pashirova T, Babaev V, Nachon F, Petrova N, Nurullin L, Zakharova L, Ilyin V, Masson P, Petrov K. New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease. Neuropharmacology 2019; 155:131-141. [DOI: 10.1016/j.neuropharm.2019.05.025] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2018] [Revised: 05/06/2019] [Accepted: 05/19/2019] [Indexed: 01/22/2023]
|
7
|
Ţînţaş ML, Gembus V, Alix F, Barré A, Coadou G, Truong L, Sebban M, Papamicaël C, Oulyadi H, Levacher V. Rational design of carbamate-based dual binding site and central AChE inhibitors by a “biooxidisable” prodrug approach: Synthesis, in vitro evaluation and docking studies. Eur J Med Chem 2018; 155:171-182. [DOI: 10.1016/j.ejmech.2018.05.057] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 04/10/2018] [Accepted: 05/31/2018] [Indexed: 12/15/2022]
|
8
|
Chierrito TP, Pedersoli-Mantoani S, Roca C, Sebastian-Pérez V, Martínez-Gonzalez L, Pérez DI, Perez C, Canales A, Cañada FJ, Campillo NE, Carvalho I, Martinez A. Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur J Med Chem 2018; 145:431-444. [DOI: 10.1016/j.ejmech.2018.01.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Revised: 12/22/2017] [Accepted: 01/04/2018] [Indexed: 02/04/2023]
|
9
|
Peauger L, Azzouz R, Gembus V, Ţînţaş ML, Sopková-de Oliveira Santos J, Bohn P, Papamicaël C, Levacher V. Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a “Bio-Oxidizable” Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation. J Med Chem 2017; 60:5909-5926. [DOI: 10.1021/acs.jmedchem.7b00702] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Ludovic Peauger
- VFP Therapies, 15 rue François
Couperin, 76000 Rouen, France
| | - Rabah Azzouz
- VFP Therapies, 15 rue François
Couperin, 76000 Rouen, France
| | - Vincent Gembus
- VFP Therapies, 15 rue François
Couperin, 76000 Rouen, France
| | - Mihaela-Liliana Ţînţaş
- Normandie
Université, COBRA, UMR 6014 et FR 3038, Univ Rouen, INSA Rouen, CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Jana Sopková-de Oliveira Santos
- Centre
d’Etudes et de Recherche sur le Médicament de Normandie, Université de Caen, Boulevard Becquerel, 14032 Caen Cedex, France
| | - Pierre Bohn
- Department
of Nuclear Medicine, Henri Becquerel Cancer Center and Rouen University
Hospital and QuantIF LITIS (Equipe d’Accueil (EA) 4108-Federation
Recherche (FR) National Center for Scientific Research (CNRS) 3638),
Faculty of Medicine, University of Rouen, Rouen 76821, France
| | - Cyril Papamicaël
- Normandie
Université, COBRA, UMR 6014 et FR 3038, Univ Rouen, INSA Rouen, CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| | - Vincent Levacher
- Normandie
Université, COBRA, UMR 6014 et FR 3038, Univ Rouen, INSA Rouen, CNRS, IRCOF, 1 rue Tesnière, 76821 Mont Saint Aignan Cedex, France
| |
Collapse
|
10
|
Liu YM, Feng YD, Lu X, Nie JB, Li W, Wang LN, Tian LJ, Liu QH. Isosteroidal alkaloids as potent dual-binding site inhibitors of both acetylcholinesterase and butyrylcholinesterase from the bulbs of Fritillaria walujewii. Eur J Med Chem 2017; 137:280-291. [PMID: 28605675 DOI: 10.1016/j.ejmech.2017.06.007] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2017] [Revised: 06/01/2017] [Accepted: 06/03/2017] [Indexed: 12/30/2022]
Abstract
Five new isosteroidal alkaloids, walujewine A (1), walujewine B (4), walujewine C (5), walujewine D (6), walujewine E (10) were isolated from the bulbs of Fritillaria walujewii together with seven known isosteroidal alkaloids (2, 3, 7-9, 11, 12). Their structures were elucidated on the basis of IR, ESI-MS, HR-ESI-MS, 1D and 2D NMR spectroscopic data analyses and single-crystal X-ray diffraction. All the isolates were tested for ChE inhibiting activity by the Ellman's method. Compounds 3-5 and 8-10 were potent dual AChE-BChE inhibitors, and compound 1 showed highly selective AChE inhibition. The structure-activity relationship of compounds 1-12 was discussed in details. And kinetic analysis showed that compounds 1, 3-5, and 8-10 were mixed-type reversible inhibitors of AChE, simultaneously binding to the catalytic and peripheral anionic sites, which was verified by in silico docking studies. The docking simulation also showed that active compound 3 and 8 created many interactions with the CAS and PAS gorges of BChE, revealing their mixed-type inhibition. ADMET analysis further confirmed the therapeutic potential of some isosteroidal alkaloids based on their high BBB-penetration.
Collapse
Affiliation(s)
- Yu-Ming Liu
- Department of Pharmacy Engineering, Tianjin University of Technology, Tianjin 300384, PR China.
| | - Ya-Dong Feng
- Department of Pharmacy Engineering, Tianjin University of Technology, Tianjin 300384, PR China
| | - Xi Lu
- Department of Pharmacy Engineering, Tianjin University of Technology, Tianjin 300384, PR China
| | - Jian-Bing Nie
- Department of Pharmacy Engineering, Tianjin University of Technology, Tianjin 300384, PR China
| | - Wei Li
- Department of Pharmacy Engineering, Tianjin University of Technology, Tianjin 300384, PR China
| | - Li-Ning Wang
- College of Traditional Chinese Medicine, Tianjin Univerisity of Traditional Chinese Medicine, Tianjin 300193, PR China
| | - Li-Jun Tian
- Department of Pharmacy Engineering, Tianjin University of Technology, Tianjin 300384, PR China
| | - Qing-Hua Liu
- Xinjiang Institute of Materia Medica, Ürümuqi 830004, PR China
| |
Collapse
|
11
|
Mantoani SP, Chierrito TPC, Vilela AFL, Cardoso CL, Martínez A, Carvalho I. Novel Triazole-Quinoline Derivatives as Selective Dual Binding Site Acetylcholinesterase Inhibitors. Molecules 2016; 21:molecules21020193. [PMID: 26861273 PMCID: PMC6273213 DOI: 10.3390/molecules21020193] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Revised: 01/30/2016] [Accepted: 02/02/2016] [Indexed: 11/22/2022] Open
Abstract
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide. Currently, the only strategy for palliative treatment of AD is to inhibit acetylcholinesterase (AChE) in order to increase the concentration of acetylcholine in the synaptic cleft. Evidence indicates that AChE also interacts with the β-amyloid (Aβ) protein, acting as a chaperone and increasing the number and neurotoxicity of Aβ fibrils. It is known that AChE has two binding sites: the peripheral site, responsible for the interactions with Aβ, and the catalytic site, related with acetylcholine hydrolysis. In this work, we reported the synthesis and biological evaluation of a library of new tacrine-donepezil hybrids, as a potential dual binding site AChE inhibitor, containing a triazole-quinoline system. The synthesis of hybrids was performed in four steps using the click chemistry strategy. These compounds were evaluated as hAChE and hBChE inhibitors, and some derivatives showed IC50 values in the micro-molar range and were remarkably selective towards hAChE. Kinetic assays and molecular modeling studies confirm that these compounds block both catalytic and peripheral AChE sites. These results are quite interesting since the triazole-quinoline system is a new structural scaffold for AChE inhibitors. Furthermore, the synthetic approach is very efficient for the preparation of target compounds, allowing a further fruitful new chemical library optimization.
Collapse
Affiliation(s)
- Susimaire P Mantoani
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, Brazil.
| | - Talita P C Chierrito
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, Brazil.
| | - Adriana F L Vilela
- Departamento de Química, Grupo de Cromatografia de Bioafinidade e Produtos Naturais, Faculdade de Filosofia Ciências e Letras de Ribeirão Preto (FFCLRP), Universidade de São Paulo, Ribeirão Preto 14040-901, Brazil.
| | - Carmen L Cardoso
- Departamento de Química, Grupo de Cromatografia de Bioafinidade e Produtos Naturais, Faculdade de Filosofia Ciências e Letras de Ribeirão Preto (FFCLRP), Universidade de São Paulo, Ribeirão Preto 14040-901, Brazil.
| | - Ana Martínez
- Centro de Investigaciones Biológicas (CIB-CSIC), Madrid 28040, Spain.
| | - Ivone Carvalho
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, Brazil.
| |
Collapse
|
12
|
Semenov VE, Zueva IV, Mukhamedyarov MA, Lushchekina SV, Kharlamova AD, Petukhova EO, Mikhailov AS, Podyachev SN, Saifina LF, Petrov KA, Minnekhanova OA, Zobov VV, Nikolsky EE, Masson P, Reznik VS. 6-Methyluracil Derivatives as Bifunctional Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease. ChemMedChem 2015; 10:1863-74. [DOI: 10.1002/cmdc.201500334] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Indexed: 11/11/2022]
Affiliation(s)
- Vyacheslav E. Semenov
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
| | - Irina V. Zueva
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
- Kazan Federal University; Kremlevskaya str. 18 Kazan 420008 Russia
| | | | - Sofya V. Lushchekina
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
- N.M. Emanuel Institute of Biochemical Physics; Kosygin str. 4 Moscow 119991 Russia
| | - Alexandra D. Kharlamova
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
| | | | - Anatoly S. Mikhailov
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
| | - Sergey N. Podyachev
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
| | - Lilya F. Saifina
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
| | - Konstantin A. Petrov
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
- Kazan Federal University; Kremlevskaya str. 18 Kazan 420008 Russia
- Kazan Institute of Biochemistry & Biophysics; Russian Academy of Sciences; Lobachevsky str. 2/31 Kazan 420111 Russia
| | - Oksana A. Minnekhanova
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
| | - Vladimir V. Zobov
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
- Kazan Federal University; Kremlevskaya str. 18 Kazan 420008 Russia
| | - Evgeny E. Nikolsky
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
- Kazan Federal University; Kremlevskaya str. 18 Kazan 420008 Russia
- Kazan State Medical University; Butlerov str. 49 Kazan 420012 Russia
- Kazan Institute of Biochemistry & Biophysics; Russian Academy of Sciences; Lobachevsky str. 2/31 Kazan 420111 Russia
| | - Patrick Masson
- Kazan Federal University; Kremlevskaya str. 18 Kazan 420008 Russia
| | - Vladimir S. Reznik
- A.E. Arbuzov Institute of Organic & Physical Chemistry, Kazan Scientific Center; Russian Academy of Sciences; Arbuzov str. 8 Kazan 420088 Russia
| |
Collapse
|
13
|
Di Pietro O, Pérez-Areales FJ, Juárez-Jiménez J, Espargaró A, Clos MV, Pérez B, Lavilla R, Sabaté R, Luque FJ, Muñoz-Torrero D. Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies. Eur J Med Chem 2014; 84:107-17. [DOI: 10.1016/j.ejmech.2014.07.021] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Revised: 06/18/2014] [Accepted: 07/06/2014] [Indexed: 11/28/2022]
|
14
|
Zimmermann M. Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors? Br J Pharmacol 2014; 170:953-67. [PMID: 23991627 DOI: 10.1111/bph.12359] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2013] [Revised: 08/04/2013] [Accepted: 08/12/2013] [Indexed: 12/11/2022] Open
Abstract
AChE enzymatic inhibition is a core focus of pharmacological intervention in Alzheimer's disease (AD). Yet, AChE has also been ascribed non-hydrolytic functions, which seem related to its appearance in various isoforms. Neuronal AChE presents as a tailed form (AChE-T) predominantly found on the neuronal synapse, and a facultatively expressed readthough form (AChE-R), which exerts short to medium-term protective effects. Notably, this latter form is also found in the periphery. While these non-hydrolytic functions of AChE are most controversially discussed, there is evidence for them being additional targets of AChE inhibitors. This review aims to provide clarification as to the role of these AChE splice variants and their interplay with other cholinergic parameters and their being targets of AChE inhibition: AChE-R is particularly involved in the mediation of (anti-)apoptotic events in cholinergic cells, involving adaptation of various cholinergic parameters and a time-dependent link to the expression of neuroprotective factors. The AChE-T C-terminus is central to AChE activity regulation, while isolated AChE-T C-terminal fragments mediate toxic effects via the α7 nicotinic acetylcholine receptor. There is direct evidence for roles of AChE-T and AChE-R in neurodegeneration and neuroprotection, with these roles involving AChE as a key modulator of the cholinergic system: in vivo data further encourages the use of AChE inhibitors in the treatment of neurodegenerative conditions such as AD since effects on both enzymatic activity and the enzyme's non-hydrolytic functions can be postulated. It also suggests that novel AChE inhibitors should enhance protective AChE-R, while avoiding the concomitant up-regulation of AChE-T.
Collapse
Affiliation(s)
- M Zimmermann
- Department of Pharmacology, School of Pharmacy, Goethe University Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
15
|
López-Iglesias B, Pérez C, Morales-García JA, Alonso-Gil S, Pérez-Castillo A, Romero A, López MG, Villarroya M, Conde S, Rodríguez-Franco MI. New Melatonin–N,N-Dibenzyl(N-methyl)amine Hybrids: Potent Neurogenic Agents with Antioxidant, Cholinergic, and Neuroprotective Properties as Innovative Drugs for Alzheimer’s Disease. J Med Chem 2014; 57:3773-85. [DOI: 10.1021/jm5000613] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Beatriz López-Iglesias
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - Concepción Pérez
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - José A. Morales-García
- Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas (IIB-CSIC), C/Arturo Duperier 4, 28029 Madrid, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), C/ Valderrebollo 5, 28031 Madrid, Spain
| | - Sandra Alonso-Gil
- Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas (IIB-CSIC), C/Arturo Duperier 4, 28029 Madrid, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), C/ Valderrebollo 5, 28031 Madrid, Spain
| | - Ana Pérez-Castillo
- Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas (IIB-CSIC), C/Arturo Duperier 4, 28029 Madrid, Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), C/ Valderrebollo 5, 28031 Madrid, Spain
| | - Alejandro Romero
- Instituto Teófilo Hernando and Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, C/Arzobispo
Morcillo 4, 28029 Madrid, Spain
| | - Manuela G. López
- Instituto Teófilo Hernando and Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, C/Arzobispo
Morcillo 4, 28029 Madrid, Spain
| | - Mercedes Villarroya
- Instituto Teófilo Hernando and Departamento de Farmacología y Terapéutica, Facultad de Medicina, Universidad Autónoma de Madrid, C/Arzobispo
Morcillo 4, 28029 Madrid, Spain
| | - Santiago Conde
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| | - María Isabel Rodríguez-Franco
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), C/Juan de la Cierva 3, 28006 Madrid, Spain
| |
Collapse
|
16
|
Viayna E, Sola I, Bartolini M, De Simone A, Tapia-Rojas C, Serrano FG, Sabaté R, Juárez-Jiménez J, Pérez B, Luque FJ, Andrisano V, Clos MV, Inestrosa NC, Muñoz-Torrero D. Synthesis and Multitarget Biological Profiling of a Novel Family of Rhein Derivatives As Disease-Modifying Anti-Alzheimer Agents. J Med Chem 2014; 57:2549-67. [DOI: 10.1021/jm401824w] [Citation(s) in RCA: 107] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Elisabet Viayna
- Laboratori de Química Farmacèutica (Unitat
Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
- Institut de Biomedicina
(IBUB), Universitat de Barcelona, E-08028 Barcelona, Spain
| | - Irene Sola
- Laboratori de Química Farmacèutica (Unitat
Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
- Institut de Biomedicina
(IBUB), Universitat de Barcelona, E-08028 Barcelona, Spain
| | - Manuela Bartolini
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro 6, I-40126 Bologna, Italy
| | - Angela De Simone
- Department for Life Quality Studies, University of Bologna, Corso d’Augusto 237, I-47921 Rimini, Italy
| | - Cheril Tapia-Rojas
- Centro de Envejecimiento
y Regeneración (CARE), Departamento de Biología Celular
y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Alameda 340, 8331150 Santiago, Chile
| | - Felipe G. Serrano
- Centro de Envejecimiento
y Regeneración (CARE), Departamento de Biología Celular
y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Alameda 340, 8331150 Santiago, Chile
| | - Raimon Sabaté
- Departament de Fisicoquímica,
Facultat de Farmàcia, Universitat de Barcelona, E-08028 Barcelona, Spain
- Institut de Nanociència
i Nanotecnologia (IN2UB), Universitat de Barcelona, E-08028 Barcelona, Spain
| | - Jordi Juárez-Jiménez
- Institut de Biomedicina
(IBUB), Universitat de Barcelona, E-08028 Barcelona, Spain
- Departament de Fisicoquímica,
Facultat de Farmàcia, Universitat de Barcelona, E-08028 Barcelona, Spain
| | - Belén Pérez
- Departament de Farmacologia,
de Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Barcelona, Spain
| | - F. Javier Luque
- Institut de Biomedicina
(IBUB), Universitat de Barcelona, E-08028 Barcelona, Spain
- Departament de Fisicoquímica,
Facultat de Farmàcia, Universitat de Barcelona, E-08028 Barcelona, Spain
| | - Vincenza Andrisano
- Department for Life Quality Studies, University of Bologna, Corso d’Augusto 237, I-47921 Rimini, Italy
| | - M. Victòria Clos
- Departament de Farmacologia,
de Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Barcelona, Spain
| | - Nibaldo C. Inestrosa
- Centro de Envejecimiento
y Regeneración (CARE), Departamento de Biología Celular
y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Alameda 340, 8331150 Santiago, Chile
| | - Diego Muñoz-Torrero
- Laboratori de Química Farmacèutica (Unitat
Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain
- Institut de Biomedicina
(IBUB), Universitat de Barcelona, E-08028 Barcelona, Spain
| |
Collapse
|
17
|
Acetylcholinesterase Protein Level Is Preserved in the Alzheimer's Brain. J Mol Neurosci 2013; 53:446-53. [DOI: 10.1007/s12031-013-0183-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2013] [Accepted: 11/12/2013] [Indexed: 01/15/2023]
|
18
|
Genest D, Rochais C, Lecoutey C, Oliveira Santos JSD, Ballandonne C, Butt-Gueulle S, Legay R, Since M, Dallemagne P. Design, synthesis and biological evaluation of novel indano- and thiaindano-pyrazoles with potential interest for Alzheimer's disease. MEDCHEMCOMM 2013. [DOI: 10.1039/c3md00041a] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
19
|
Antequera D, Bolos M, Spuch C, Pascual C, Ferrer I, Fernandez-Bachiller MI, Rodríguez-Franco MI, Carro E. Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on Aβ accumulation and cell death: involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiol Dis 2012; 46:682-91. [PMID: 22426395 DOI: 10.1016/j.nbd.2012.03.009] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2011] [Revised: 02/06/2012] [Accepted: 03/01/2012] [Indexed: 10/28/2022] Open
Abstract
Several studies have implicated the enzyme acetylcholinesterase (AChE) as well as several biometals in the pathogenesis of Alzheimer's disease (AD). A multifunctional molecule, the hybrid tacrine-8-hydroxyquinoline (named IQM-622), displays cholinergic, antioxidant, copper-complexing and neuroprotective properties. Using in vitro and in vivo models, we investigated the modulating effects of IQM-622 on amyloid β-protein (Aβ)-induced pathology as well as on chemically induced neurodegeneration by domoic acid. In the first experimental model, we observed a significant decrease in brain Aβ deposits in IQM-622-treated APP/Ps1 mice for four weeks. Moreover, IQM-622 promoted the degradation of intracellular Aβ in astrocytes, and protected against Aβ toxicity in cultured astrocytes and neurons. These findings suggest that the neuroprotective effect of IQM-622 is not only related to AChE inhibition, but also involves other mechanisms, including the modulation of Aβ-degradation pathways in AD brain. In this study we also compare the neuronal loss in CA1 hippocampal field of AD patients and of mice treated with domoic acid, giving similar patterns. Thus, we used a second experimental model by killing hippocampal neurons by domoic acid damage, in which IQM-622 increased survival in the CA1 and dentate gyrus regions of the hippocampus. Our observations suggest that administration of IQM-622 may have significant beneficial effects in neurodegenerative diseases, including AD, which course with acute or progressive neuronal death.
Collapse
Affiliation(s)
- Desiree Antequera
- Neuroscience Group, Instituto de Investigación Hospital 12 de Octubre i+12, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Fernández-Bachiller MI, Pérez C, Monjas L, Rademann J, Rodríguez-Franco MI. New Tacrine–4-Oxo-4H-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Cholinergic, Antioxidant, and β-Amyloid-Reducing Properties. J Med Chem 2012; 55:1303-17. [DOI: 10.1021/jm201460y] [Citation(s) in RCA: 210] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- María Isabel Fernández-Bachiller
- Instituto de Química
Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
- Medicinal Chemistry, Institut für Molekulare Pharmakologie (FMP),
Campus Berlin-Buch, Robert-Rössle Strasse 10, 13125 Berlin,
Germany
| | - Concepción Pérez
- Instituto de Química
Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
| | - Leticia Monjas
- Instituto de Química
Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
| | - Jörg Rademann
- Medicinal Chemistry, Institut für Molekulare Pharmakologie (FMP),
Campus Berlin-Buch, Robert-Rössle Strasse 10, 13125 Berlin,
Germany
- Medicinal Chemistry,
Institute
of Pharmacy, Leipzig University, Brüderstrasse
34, 04103 Leipzig, Germany
| | - María Isabel Rodríguez-Franco
- Instituto de Química
Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
| |
Collapse
|
21
|
Galdeano C, Viayna E, Sola I, Formosa X, Camps P, Badia A, Clos MV, Relat J, Ratia M, Bartolini M, Mancini F, Andrisano V, Salmona M, Minguillón C, González-Muñoz GC, Rodríguez-Franco MI, Bidon-Chanal A, Luque FJ, Muñoz-Torrero D. Huprine–Tacrine Heterodimers as Anti-Amyloidogenic Compounds of Potential Interest against Alzheimer’s and Prion Diseases. J Med Chem 2012; 55:661-9. [DOI: 10.1021/jm200840c] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Carles Galdeano
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| | - Elisabet Viayna
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| | - Irene Sola
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| | - Xavier Formosa
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
| | - Pelayo Camps
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| | - Albert Badia
- Departament
de Farmacologia, de
Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra,
Barcelona, Spain
| | - M. Victòria Clos
- Departament
de Farmacologia, de
Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra,
Barcelona, Spain
| | - Júlia Relat
- Departament
de Farmacologia, de
Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra,
Barcelona, Spain
| | - Míriam Ratia
- Departament
de Farmacologia, de
Terapèutica i de Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193 Bellaterra,
Barcelona, Spain
| | - Manuela Bartolini
- Department
of Pharmaceutical
Sciences, Alma Mater Studiorum, Bologna University, Via Belmeloro 6, I-40126 Bologna, Italy
| | - Francesca Mancini
- Department
of Pharmaceutical
Sciences, Alma Mater Studiorum, Bologna University, Via Belmeloro 6, I-40126 Bologna, Italy
| | - Vincenza Andrisano
- Department
of Pharmaceutical
Sciences, Alma Mater Studiorum, Bologna University, Via Belmeloro 6, I-40126 Bologna, Italy
| | - Mario Salmona
- Department of Molecular Biochemistry
and Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
| | - Cristina Minguillón
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
| | | | | | - Axel Bidon-Chanal
- Departament de Fisicoquímica,
Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028 Barcelona, Spain
| | - F. Javier Luque
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
- Departament de Fisicoquímica,
Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028 Barcelona, Spain
| | - Diego Muñoz-Torrero
- Laboratori
de Química
Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, Universitat de Barcelona, Av. Diagonal 643, E-08028
Barcelona, Spain
- Institut
de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
| |
Collapse
|
22
|
|
23
|
Viayna E, Gómez T, Galdeano C, Ramírez L, Ratia M, Badia A, Clos MV, Verdaguer E, Junyent F, Camins A, Pallàs M, Bartolini M, Mancini F, Andrisano V, Arce MP, Rodríguez-Franco MI, Bidon-Chanal A, Luque FJ, Camps P, Muñoz-Torrero D. Novel Huprine Derivatives with Inhibitory Activity toward β-Amyloid Aggregation and Formation as Disease-Modifying Anti-Alzheimer Drug Candidates. ChemMedChem 2010; 5:1855-70. [DOI: 10.1002/cmdc.201000322] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
24
|
Camps P, Formosa X, Galdeano C, Gómez T, Muñoz-Torrero D, Ramírez L, Viayna E, Gómez E, Isambert N, Lavilla R, Badia A, Clos MV, Bartolini M, Mancini F, Andrisano V, Bidon-Chanal A, Huertas Ó, Dafni T, Luque FJ. Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. Chem Biol Interact 2010; 187:411-5. [DOI: 10.1016/j.cbi.2010.02.013] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2009] [Revised: 01/27/2010] [Accepted: 02/09/2010] [Indexed: 10/19/2022]
|
25
|
Fernández-Bachiller MI, Pérez C, González-Muñoz GC, Conde S, López MG, Villarroya M, García AG, Rodríguez-Franco MI. Novel Tacrine−8-Hydroxyquinoline Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Neuroprotective, Cholinergic, Antioxidant, and Copper-Complexing Properties. J Med Chem 2010; 53:4927-37. [DOI: 10.1021/jm100329q] [Citation(s) in RCA: 212] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
| | - Concepción Pérez
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
| | - Gema C. González-Muñoz
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
| | - Santiago Conde
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
| | - Manuela G. López
- Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Arzobispo Morcillo 4, 28029 Madrid, Spain
- Departamento de Farmacología y Terapéutica, Facultad de Medicina
| | - Mercedes Villarroya
- Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Arzobispo Morcillo 4, 28029 Madrid, Spain
- Departamento de Farmacología y Terapéutica, Facultad de Medicina
| | - Antonio G. García
- Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Arzobispo Morcillo 4, 28029 Madrid, Spain
- Departamento de Farmacología y Terapéutica, Facultad de Medicina
- Servicio de Farmacología Clínica, Hospital Universitario de la Princesa, Diego de León 62, 28006 Madrid, Spain
| | - María Isabel Rodríguez-Franco
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain
| |
Collapse
|
26
|
Bartolini M, Andrisano V. Strategies for the Inhibition of Protein Aggregation in Human Diseases. Chembiochem 2010; 11:1018-35. [DOI: 10.1002/cbic.200900666] [Citation(s) in RCA: 102] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
27
|
Spuch C, Antequera D, Isabel Fernandez-Bachiller M, Isabel Rodríguez-Franco M, Carro E. A New Tacrine–Melatonin Hybrid Reduces Amyloid Burden and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease. Neurotox Res 2009; 17:421-31. [DOI: 10.1007/s12640-009-9121-2] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2009] [Revised: 09/15/2009] [Accepted: 09/15/2009] [Indexed: 12/31/2022]
|
28
|
Zheng H, Youdim MBH, Fridkin M. Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. J Med Chem 2009; 52:4095-8. [PMID: 19485411 DOI: 10.1021/jm900504c] [Citation(s) in RCA: 105] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A novel strategy to develop site-activated multifunctional chelators for targeting multiple etiologies of Alzheimer's disease is reported. The novel prochelator HLA20A with improved cytotoxicity shows little affinity for metal ions until it is activated by binding and inhibiting acetylcholinesterase (AChE), releasing an active chelator HLA20 that modulates amyloid precursor protein (APP) regulation and beta-amyloid (Abeta) reduction, suppresses oxidative stress, and passivates excess metal ions (Fe, Cu, and Zn) in the brain.
Collapse
Affiliation(s)
- Hailin Zheng
- Department of Organic Chemistry, the Weizmann Institute of Science, Rehovot 76100, Israel
| | | | | |
Collapse
|
29
|
Camps P, Formosa X, Galdeano C, Muñoz-Torrero D, Ramírez L, Gómez E, Isambert N, Lavilla R, Badia A, Clos MV, Bartolini M, Mancini F, Andrisano V, Arce MP, Rodríguez-Franco MI, Huertas Ó, Dafni T, Luque FJ. Pyrano[3,2-c]quinoline−6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds. J Med Chem 2009; 52:5365-79. [DOI: 10.1021/jm900859q] [Citation(s) in RCA: 144] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Pelayo Camps
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Diagonal 643, E-08028, Barcelona, Spain
| | - Xavier Formosa
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Diagonal 643, E-08028, Barcelona, Spain
| | - Carles Galdeano
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Diagonal 643, E-08028, Barcelona, Spain
| | - Diego Muñoz-Torrero
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Diagonal 643, E-08028, Barcelona, Spain
| | - Lorena Ramírez
- Laboratori de Química Farmacèutica (Unitat Associada al CSIC), Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Diagonal 643, E-08028, Barcelona, Spain
| | - Elena Gómez
- Institute for Research in Biomedicine, Barcelona Science Park, Baldiri Reixac 10-12, E-08028, Barcelona, Spain
| | - Nicolás Isambert
- Institute for Research in Biomedicine, Barcelona Science Park, Baldiri Reixac 10-12, E-08028, Barcelona, Spain
| | - Rodolfo Lavilla
- Institute for Research in Biomedicine, Barcelona Science Park, Baldiri Reixac 10-12, E-08028, Barcelona, Spain
- Laboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII, s/n, E-08028, Barcelona, Spain
| | - Albert Badia
- Departament de Farmacologia, Terapèutica i Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193, Bellaterra, Barcelona, Spain
| | - M. Victòria Clos
- Departament de Farmacologia, Terapèutica i Toxicologia, Institut de Neurociències, Universitat Autònoma de Barcelona, E-08193, Bellaterra, Barcelona, Spain
| | - Manuela Bartolini
- Department of Pharmaceutical Sciences, Alma Mater Studiorum, Bologna University, Via Belmeloro 6, I-40126, Bologna, Italy
| | - Francesca Mancini
- Department of Pharmaceutical Sciences, Alma Mater Studiorum, Bologna University, Via Belmeloro 6, I-40126, Bologna, Italy
| | - Vincenza Andrisano
- Department of Pharmaceutical Sciences, Alma Mater Studiorum, Bologna University, Via Belmeloro 6, I-40126, Bologna, Italy
| | - Mariana P. Arce
- Instituto de Química Médica (CSIC), Juan de la Cierva, 3, E-28006, Madrid, Spain
| | | | - Óscar Huertas
- Departament de Fisicoquímica, Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Diagonal 643, E-08028, Barcelona, Spain
| | - Thomai Dafni
- Departament de Fisicoquímica, Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Diagonal 643, E-08028, Barcelona, Spain
| | - F. Javier Luque
- Departament de Fisicoquímica, Facultat de Farmàcia, and Institut de Biomedicina (IBUB), Universitat de Barcelona, Av. Diagonal 643, E-08028, Barcelona, Spain
| |
Collapse
|
30
|
Fernández-Bachiller MI, Pérez C, Campillo NE, Páez JA, González-Muñoz GC, Usán P, García-Palomero E, López M, Villarroya M, García A, Martínez A, Rodríguez-Franco MI. Tacrine-Melatonin Hybrids as Multifunctional Agents for Alzheimer's Disease, with Cholinergic, Antioxidant, and Neuroprotective Properties. ChemMedChem 2009; 4:828-41. [DOI: 10.1002/cmdc.200800414] [Citation(s) in RCA: 123] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
31
|
Fisher A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics 2008; 5:433-42. [PMID: 18625455 PMCID: PMC5084245 DOI: 10.1016/j.nurt.2008.05.002] [Citation(s) in RCA: 110] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The only prescribed drugs for treatment of Alzheimer's disease (AD) are acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine, and tacrine) and memantine, an NMDA antagonist. These drugs ameliorate mainly the symptoms of AD, such as cognitive impairments, rather than halting or preventing the causal neuropathology. There is currently no cure for AD and there is no way to stop its progression, yet there are numerous therapeutic approaches directed against various pathological hallmarks of AD that are extensively being pursued. In this context, the three major hallmark characteristics of AD (i.e., the CNS cholinergic hypofunction, formation of beta-amyloid plaques, and tangles containing hyperphosphorylated tau proteins) are apparently linked. Such linkages may have therapeutic implications, and this review is an attempt to analyze these versus the advantages and drawbacks of some cholinergic compounds, such as acetylcholinesterase inhibitors, M1 muscarinic agonists, M2 antagonists, and nicotinic agonists. Among the reviewed treatments, M1 selective agonists emerge, in particular, as potential disease modifiers.
Collapse
Affiliation(s)
- Abraham Fisher
- Israel Institute for Biological Research, PO Box 19, Ness-Ziona, Israel.
| |
Collapse
|